Aristo Bio Tech and Lifescience Limited

As of March 31, 2025, Aristo Bio Tech and Lifescience Limited carries a market capitalization of 791.07M, placing it among publicly traded companies globally. Its enterprise value stands at 998.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Aristo Bio Tech and Lifescience Limited has 6.81M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Aristo Bio Tech and Lifescience Limited maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Aristo Bio Tech and Lifescience Limited's stock has declined approximately 34.67% over the past 52 weeks. The 50-day moving average sits at 102.25, while the 200-day moving average is 114.09.

As of March 31, 2025, Aristo Bio Tech and Lifescience Limited holds 10.90M in cash and equivalents against 218.54M in total debt, resulting in a net debt position of 207.64M. Total book value stands at 373.31M, with working capital of 201.85M providing operational flexibility.